NRX Pharmaceuticals posts Q3 loss and reports first revenue after Dura Medical acquisition

NRX Pharmaceuticals Inc. reported a loss from operations of $4.0 million for the quarter ended September 30, 2025, compared to a loss of $3.0 million in the same quarter of 2024. The increase was mainly due to $0.8 million in additional research and development expenses and $0.4 million in higher general and administrative costs. As of September 30, 2025, the company held approximately $7.1 million in cash and cash equivalents, rising to $10.3 million after including subsequent receipts. NRX Pharmaceuticals recorded its first revenue of $0.2 million for the quarter, following the acquisition of Dura Medical, which contributed results for 22 days. The company expects revenue growth in future periods through additional acquisitions and organic expansion of its HOPE clinics, which currently operate three facilities in Florida with plans to reach six or more by year-end. Management anticipates its cash position will support operations at least through the second quarter of 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9576790-en) on November 17, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)